Waldencast plc filings document the company's foreign-issuer reporting for a beauty and wellness platform with Obagi Medical and Milk Makeup as operating brands. Form 6-K reports furnish financial results, interim consolidated financial statements, earnings-date notices, and business updates covering skincare, cosmetics, medical aesthetics, distribution, operating expenses, and brand performance.
The filing record also covers annual general meeting voting, director re-appointments, auditor ratification, credit-facility agreements, trademark transfer and coexistence agreements involving the Obagi mark in Japan, and registration-statement incorporation references. Other disclosures address the completed SEC investigation connected to prior financial restatement matters and material weaknesses in internal control over financial reporting.
Waldencast plc filed a Form 6-K to provide its unaudited interim consolidated financial statements for the six months ended June 30, 2025. These H1 2025 interim financials are furnished as Exhibit 99.1.
The filing also lists several material agreements as exhibits, including a Credit Agreement dated November 14, 2025 involving Milk Makeup LLC, Obagi Cosmeceuticals LLC, Waldencast Partners plc as parent guarantor, various lenders and LSSF II Offshore Investments, LP as administrative agent. In addition, it includes a Trademark Transfer Agreement and a Trademark Coexistence Agreement, both dated November 13, 2025, between Rohto Pharmaceutical Co., Ltd. and Obagi Cosmeceuticals LLC.
The report and its exhibits are incorporated by reference into Waldencast’s existing registration statements on Form S-8 and Form F-3, meaning these interim financials and agreements now form part of those shelf and incentive plan disclosures.
Waldencast plc reported updates via a Form 6-K, noting the sale of its rights to the “Obagi” trademark in Japan and the entry into a new credit facility. The company characterized these steps as strengthening its balance sheet.
A press release dated November 14, 2025 is attached as Exhibit 99.1 for further details. The information in this report, including the exhibit, is designated as not “filed” under Section 18 of the Exchange Act.